D-mannose alleviates rotenone-induced PD mouse model through microbiota-gut-brain axis

Parkinson’s disease (PD) is the second most common neurological degenerative disease in the elderly. Disruption of gut-brain axis crosstalk has been shown to be associated with the pathogenesis of PD. Although drug treatments for PD have been in development for decades, there is currently no drug or therapy that can completely cure PD. Therefore, there is an urgent need to discover new drugs to develop effective PD treatment strategies. D-mannose is a natural, bioactive monosaccharide that is a popular nutritional and health-beneficial food supplement worldwide. However, whether it has a neuroprotective effect on PD is still unclear. C57BL6/J mice aged 8–9 weeks were orally administrated with rotenone solution once a day for four weeks and drinking D-mannose for the following 2 weeks. Fresh fecal pellets from each mouse were used for 16 S rRNA sequencing. We found that D-mannose treatment alleviated motor symptoms, gastrointestinal dysfunctions in rotenone-induced PD mice. 16 S rRNA sequencing found that microbiota alterations were reversed by D-mannose in rotenone-induced PD mice. D-mannose treatment suppressed neuroinflammation by TLR4/MyD88/NF-κB pathway in the SN. This study proved that the importance of D-mannose on PD, and explored the potential mechanism of gut-brain axis in PD pathogenesis, providing a new target for clinical treatment of PD.

• Publication year

  2026

• Venue

  Scientific Reports

• Publication date

  2026-01-19

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1038/s41598-026-36272-0PMID 41554950PMCID 12891537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The pathogenesis of Parkinson's disease.

  2024cited by this paper
• Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology and behavior impairments.

  2024cited by this paper
• Mannose enhances intestinal immune barrier function and dextran sulfate sodium salt-induced colitis in mice by regulating intestinal microbiota

  2024cited by this paper
• α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease

  2024cited by this paper
• Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota–gut–brain axis

  2024cited by this paper
• Protein-protein interactions regulating α-synuclein pathology.

  2024cited by this paper
• Neuroprotection of rhubarb extract against cerebral ischaemia-reperfusion injury via the gut-brain axis pathway.

  2024cited by this paper
• Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management.

  2024cited by this paper
• Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions

  2023cited by this paper
• D-Mannose prevents bone loss under weightlessness

  2023cited by this paper
• Unraveling the gut-brain axis: the impact of steroid hormones and nutrition on Parkinson’s disease

  2023cited by this paper
• Does Gut Brain Axis has an impact on Parkinson's Disease (PD)?

  2023cited by this paper
• Immunosenescence as a convergence pathway in neurodegeneration.

  2023cited by this paper
• Butyrate ameliorates chronic alcoholic central nervous damage by suppressing microglia-mediated neuroinflammation and modulating the microbiome-gut-brain axis.

  2023cited by this paper
• European Academy of Neurology/Movement Disorder Society ‐ European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies

  2022cited by this paper
• D-mannose for preventing and treating urinary tract infections.

  2022cited by this paper
• α-Synuclein in synaptic function and dysfunction.

  2022cited by this paper
• Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Neuroinflammation: Implications for Neurodegenerative Disease Treatment.

  2022cited by this paper
• Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment

  2022cited by this paper
• Association of Diet and Physical Activity With All-Cause Mortality Among Adults With Parkinson Disease

  2022cited by this paper
• European Academy of Neurology/Movement Disorder Society‐European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies

  2022cited by this paper
• Novel compound FLZ alleviates rotenone-induced PD mouse model by suppressing TLR4/MyD88/NF-κB pathway through microbiota–gut–brain axis

  2021cited by this paper
• Fecal microbiota transplantation protects rotenone-induced Parkinson’s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis

  2021cited by this paper
• d-mannose suppresses oxidative response and blocks phagocytosis in experimental neuroinflammation

  2021cited by this paper
• Electroacupuncture Alleviates Neuroinflammation and Motor Dysfunction by Regulating Intestinal Barrier Function in a Mouse Model of Parkinson Disease.

  2021cited by this paper
• Glucose metabolic crosstalk and regulation in brain function and diseases.

  2021cited by this paper
• Parkinson's disease

  2021cited by this paper
• The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017.

  2020cited by this paper
• Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease

  2019cited by this paper
• Mechanistic comparison between MPTP and rotenone neurotoxicity in mice

  2019cited by this paper
• Probiotics modulate the microbiota–gut–brain axis and improve memory deficits in aged SAMP8 mice

  2019cited by this paper
• Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway.

  2018cited by this paper
• Role of TLR4 in the gut-brain axis in Parkinson’s disease: a translational study from men to mice

  2018cited by this paper
• Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease.

  2018cited by this paper
• Longitudinal Analysis of Fecal Microbiome and Pathologic Processes in a Rotenone Induced Mice Model of Parkinson’s Disease

  2018cited by this paper
• Updating Our Definitions of Parkinson’s Disease for a Molecular Age

  2018cited by this paper
• Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease

  2018cited by this paper
• The Role of Astrocyte Dysfunction in Parkinson’s Disease Pathogenesis

  2017cited by this paper
• Large-scale identification of clinical and genetic predictors of Parkinson’s disease motor progression in newly-diagnosed patients: a longitudinal cohort study and validation

  2017cited by this paper
• Alzheimer’s disease and gut microbiota

  2016cited by this paper
• d-Mannose: Properties, Production, and Applications: An Overview.

  2016cited by this paper
• Brain-gut-microbiota axis in Parkinson's disease.

  2015cited by this paper
• Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors

  2015cited by this paper
• An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions.

  2015cited by this paper
• The Metabolic Origins of Mannose in Glycoproteins*♦

  2014cited by this paper
• Interplay of LRRK2 with chaperone-mediated autophagy

  2013cited by this paper
• Effects of oral administration of rotenone on gastrointestinal functions in mice

  2013cited by this paper
• A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease

  2011cited by this paper
• Gastrointestinal Dysfunction in Parkinson’s Disease

  2011cited by this paper
• Rotenone, Paraquat, and Parkinson’s Disease

  2011cited by this paper
• Progression of Parkinson's Disease Pathology Is Reproduced by Intragastric Administration of Rotenone in Mice

  2010cited by this paper
• Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders

  2010cited by this paper
• Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy

  2007cited by this paper
• Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4‐phenylbutyrate, a chemical chaperone

  2007cited by this paper
• Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.

  2004influential reference
• Gastrointestinal dysfunction in Parkinson's disease.

  2003cited by this paper

• No citing papers are available for this paper.